Search Results - "Van Seventer, E.E."

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours by Corcoran, R.B., Do, K.T., Cleary, J.M., Parikh, A.R., Yeku, O.O., Weekes, C.D., Veneris, J., Ahronian, L.G., Mauri, G., Van Seventer, E.E., Fetter, I.J., Gurski, J.M., Matulonis, U.A., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J.W., Heist, R.S., Shapiro, G.I.

Get full text

447PD - Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours by Corcoran, R.B., Do, K.T., Cleary, J.M., Parikh, A.R., Yeku, O.O., Weekes, C.D., Veneris, J., Ahronian, L.G., Mauri, G., Van Seventer, E.E., Fetter, I.J., Gurski, J.M., Matulonis, U.A., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J.W., Heist, R.S., Shapiro, G.I.

“…MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in preclinical RAS…”
Get full text